Get the Stockscreener App
0.3192
5.95%
-0.0202
After Hours:
.33
0.0108
+3.38%
Lipella Pharmaceuticals Inc stock is traded at $0.3192, with a volume of 708.31K.
It is down -5.95% in the last 24 hours and down -23.98% over the past month.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
See More
Previous Close:
$0.3394
Open:
$0.34
24h Volume:
708.31K
Relative Volume:
0.67
Market Cap:
$3.09M
Revenue:
-
Net Income/Loss:
$-4.74M
P/E Ratio:
-0.4929
EPS:
-0.6476
Net Cash Flow:
$-3.46M
1W Performance:
-22.67%
1M Performance:
-23.98%
6M Performance:
-57.10%
1Y Performance:
-71.24%
1-Day Range:
$0.302
$0.3499
1-Week Range:
$0.302
$0.42
52-Week Range:
$0.302
$1.50
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Name
Lipella Pharmaceuticals Inc
Sector
Industry
Phone
412-901-0315
Address
400 N LEXINGTON ST, PITTSBURGH
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewswire
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily
Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily
Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily
Recent Insider Activity Suggests Potential Gains for KE Holdings Inc ADR (BEKE) - Knox Daily
Lipella Pharmaceuticals Inc [LIPO] is -57.84% lower this YTD. Is it still time to buy? - The DBT News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Huge semiconductor deal has eyes on this tech co 👀 - RagingBull
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - GlobeNewswire
Interstitial Cystitis Market Size is Set for Rapid Growth as - openPR
Sky Quarry Announces Closing of Public Offering of $6.7 Million - The Manila Times
TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit - GlobeNewswire
Expion360 Inc’s latest rating changes from various analysts - Knox Daily
Insider Buying: Kaufman Jonathan H, Lipella Pharmaceuticals Inc [LIPO] insider invested 10,000 shares - Knox Daily
The time has not yet come to remove your chips from the table: Lipella Pharmaceuticals Inc (LIPO) - SETE News
Lipella Pharmaceuticals Inc Inc. (LIPO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
PRISM MarketView Features Q&A with Dr. Michael Chancellor: - GlobeNewswire
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month - Morningstar
Lipella reports positive phase 2a trial results for OLP treatment - Investing.com
Lipella Pharmaceuticals Reports Encouraging Early - GlobeNewswire
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus - StockTitan
A year in review: Lipella Pharmaceuticals Inc (LIPO)’s performance in the last year - US Post News
Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex
Lipella stock soars 200% on Phase 2 study initiation - MSN
Matthew E Korenberg At Ligand Pharmaceuticals Executes Options Exercise, Realizing $260K - Benzinga
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
John Deneen Collins Sells 85,126 Shares of LivePerson, Inc. (NASDAQ:LPSN) Stock - Defense World
Lepidico Wins Crucial Road Access Dispute - TipRanks
Louisiana-Pacific director sells $245,750 in company stock By Investing.com - Investing.com Canada
LivePerson CFO and COO sells over $89k in company stock - Investing.com
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
A stock that deserves closer examination: Lipella Pharmaceuticals Inc (LIPO) - US Post News
Moody’s to withdraw Lippo Malls Indonesia Retail Trust’s credit ratings - The Edge Singapore
UK Government gets behind Lepidico’s process technologies - Mining.com.au
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00 - MarketBeat
Understanding the Risks of Investing in Lipella Pharmaceuticals Inc (LIPO) - Knox Daily
Stock Surge: Lipella Pharmaceuticals Inc (LIPO) Closes at 0.40, Marking a 6.96 Increase/Decrease - The Dwinnex
A closer look at LIPO’s price-to-free cash flow ratio - US Post News
Interstitial Cystitis Market Growth Anticipated by 2032 | Companies includes Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation - Barchart
Lipella Pharmaceuticals announces board election and reverse stock split - Investing.com
Lipella Pharmaceuticals Inc [LIPO] Investment Guide: What You Need to Know - Knox Daily
Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment - MSN
A Guide To The Risks Of Investing In Lipella Pharmaceuticals Inc (LIPO) - Knox Daily
LIPO’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):